BIOMAT Database Logo BIOMAT Database Logo

Osteoporosis prevention with sex hormone replacement therapy. 1994

S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Interdisciplinary Group on Osteoporosis, Free University of Brussels (VUB-ULB), Hôpital Saint-Pierre, Belgium.

It was suggested as long ago as 1941 that there might be a connection between the menopause and osteoporosis. Since then, abundant data have confirmed that hypothesis as well as showing that such osteoporosis may be prevented by estrogen supplementation (ERT--estrogen replacement therapy). In estrogen deficiency, increased bone resorption takes place in the process of bone remodeling, leading to bone loss. The bone loss occurs universally but to the greatest extent at sites rich in trabecular bone. There are uncertainties concerning extent of bone loss at various sites at different ages, effect of ERT at varying sites and different ages, degree of fracture prevention, and relationship between duration of therapy and fracture risk. That optimal fracture risk is not being attained now on a population basis is due to apparently low acceptance of ERT by patients and lack of strenuous effort in that direction by physicians.

UI MeSH Term Description Entries
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015663 Osteoporosis, Postmenopausal Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency. Bone Loss, Perimenopausal,Bone Loss, Postmenopausal,Perimenopausal Bone Loss,Postmenopausal Bone Loss,Postmenopausal Osteoporosis,Osteoporosis, Post-Menopausal,Bone Losses, Perimenopausal,Bone Losses, Postmenopausal,Osteoporoses, Post-Menopausal,Osteoporoses, Postmenopausal,Osteoporosis, Post Menopausal,Perimenopausal Bone Losses,Post-Menopausal Osteoporoses,Post-Menopausal Osteoporosis,Postmenopausal Bone Losses,Postmenopausal Osteoporoses
D015914 Estrogen Replacement Therapy The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy. Hormone Replacement Therapy, Post-Menopausal,Postmenopausal Hormone Replacement Therapy,Replacement Therapy, Estrogen,Estrogen Progestin Combination Therapy,Estrogen Progestin Replacement Therapy,Estrogen Replacement,Replacement, Estrogen,Therapy, Estrogen Replacement,Estrogen Replacement Therapies,Estrogen Replacements,Hormone Replacement Therapy, Post Menopausal,Replacement Therapies, Estrogen,Replacements, Estrogen,Therapies, Estrogen Replacement
D016723 Bone Remodeling The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS. Bone Turnover,Bone Turnovers,Remodeling, Bone,Turnover, Bone,Turnovers, Bone
D050723 Fractures, Bone Breaks in bones. Bone Fractures,Broken Bones,Spiral Fractures,Torsion Fractures,Bone Fracture,Bone, Broken,Bones, Broken,Broken Bone,Fracture, Bone,Fracture, Spiral,Fracture, Torsion,Fractures, Spiral,Fractures, Torsion,Spiral Fracture,Torsion Fracture

Related Publications

S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Hormone replacement therapy for osteoporosis prevention.
July 1997, The British journal of general practice : the journal of the Royal College of General Practitioners,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Prevention and treatment of osteoporosis with hormone replacement therapy.
January 1993, International journal of fertility and menopausal studies,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
[Some problems of postmenopausal osteoporosis prevention with hormone replacement therapy].
June 2003, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Hormone replacement therapy and the prevention of postmenopausal osteoporosis.
September 2014, Przeglad menopauzalny = Menopause review,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Reasonable osteoporosis prevention: hormone replacement therapy, SERM, or bisphosphonate?
January 2000, Joint bone spine,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Hormone replacement therapy for prevention and treatment of osteoporosis.
November 1993, The American journal of medicine,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Hormone replacement therapy in the prevention and treatment of osteoporosis.
January 1997, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
[Hormone replacement therapy and osteoporosis].
January 2000, Bratislavske lekarske listy,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
[Hormone replacement therapy and osteoporosis].
March 2004, Clinical calcium,
S Rozenberg, and J Vandromme, and M Kroll, and A Pastijn, and M Degueldre
Hormone replacement therapy and osteoporosis.
October 1997, Irish medical journal,
Copied contents to your clipboard!